Committee Co-Chairs


Life Sciences Future – BioPharm 

Company Presentations

Toggle between the Company Presentation names below to learn more about each company. 

Click below to learn more.

Teresa Whalen, CEO

CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, Influenza and other viral infectious diseases.


Drusolv Therapeutics

John Edwards, CEO

Drusolv Threapeuticis is a clinical-stage drug company developing a high-dose oral statin for early intervention in age-related macular degeneration (AMD).


Evrys Bio

Lillian W. Chiang, Ph.D., President & CEO

Evrys Bio antivirals target non-viral human proteins, known as sirtuins, enhancing their natural ability to fight powerful infections.



Matt Handel, CEO

ExpressCells leverages proprietary gene-editing tools and the power of CRISPR to create custom, knock-in cell lines for drug discovery, toxicology, and other biologic research.



Geistlich Pharma (oncology)

Greg Bosch, CEO

Developing a product for cancers with high unmet need; e.g., pancreatic, ovarian, mesotheliomas, triple negative breast and other cancers.


Levolta Pharmaceuticals

Renee Stewart, Co-Founder & CSO

Developing innovative therapeutic products for patients suffering from illnesses associated with rheumatology, immunology and oncology.


Maxwell Biosciences Inc.

Joshua McClure, CEO

Maxwell Biosciences is a preclinical stage drug platform company actively developing an entirely new class of patented, virucidal, small molecule drugs called Maxwell’s Peptoids™.


MBF Therapeutics

Thomas Tillett, CEO

MBF Therapeutics is a life science company focused on the development of gene-based, immunotherapeutic vaccines for use in veterinary medicine and human health.


MSL Pharma

Yarom Cohen, CEO

Seed stage company developing new drugs to treat obesity, metabolic syndrome, different forms of cancer, Alzheimer’s Disease and Parkinson’s Disease.



Nikolaos Tezapsidis, CEO

Neurotez, Inc. is a private corporation whose primary goal is to develop a Leptin product as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk.


OcuMedic, Inc.

Keith Ignotz, CEO

Proprietary technology based on a novel drug-eluting contact lens to provide timed drug delivery directly to eye; improving recovery, reducing cost for millions after eye surgery and LASIK.



Sebastian Franzinger, VP, Finance & Business Development

Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class compounds that selectively target G protein-coupled receptors for oncology.


PepVax, Inc.

Mahesh Narayanan, CEO

PepVax, Inc. is an early-stage biotechnology company developing a novel DNA plasmid delivery system using the patient’s own cells to manufacture the required proteins, T-cells and antibodies in vivo for cancers, infectious and genetic diseases.



Zeev Dvashi, CEO

Plas-Free focuses on the development of an innovative medical device ClearPlasma™ that modifies human plasma to improve treatment for massive bleeding.


PolyCore Therapeutics

Kelly Beck, CEO

PolyCore Therapeutics is developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders. PolyCore is currently conducting preclinical studies for a novel small molecule for treatment of Parkinson’s Disease.


SFA Therapeutics, Inc.

Ira Spector, CEO

SFA Therapeutics, Inc. is a development-stage bio-pharmaceutical startup company focused on a new advancement in the treatment of chronic inflammatory disease– the use of microbiome-derived metabolites as drugs.


TargetGene Biotechnologies LTD

Yoel Shiboleth, CEO & Co-Founder

Developing cell therapies for immune disorders, cancer and genetic diseases. TargetGene is a pioneer in the field of genome editing and owns the first RNA-guided nuclease system ever invented.


Virion Therapeutics

Andrew Luber, President & CEO, Director

Commited to developing innovative immune-based treatments for virally associated cancers and chronic viral infections utilizing the first genetic construct checkpoint inhibitor given via vaccination.


Yesse Technologies

Charlotte D’Hulst, CEO

Developing a technology platform by merging the biology of the nose with cutting-edge chip nanotechnology for odor-based disease diagnostics.



Questions about the event?  Please contact lifesciencesfuturehelp@gmail.com.

650 E. Swedesford Rd | Ste 190 Wayne PA | 19087